Straits Times Index
3,074.18 -2.98 (-0.10%) Nikkei
33,226.65 +450.83 (+1.38%) Hang Seng
16,327.86 0.00 (0.00%) FTSE 100
7,489.84 -23.12 (-0.31%) Bitcoin USD
44,058.17 +2,256.91 (+5.40%) CMC Crypto 200
901.14 +40.60 (+4.72%)
AbbVie Inc. (ABBV)
After hours:
| Previous close | 144.15 |
| Open | 144.11 |
| Bid | 144.33 x 1000 |
| Ask | 144.36 x 800 |
| Day's range | 142.66 - 145.08 |
| 52-week range | 130.96 - 168.11 |
| Volume | |
| Avg. volume | 4,918,626 |
| Market cap | 255.244B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 39.61 |
| EPS (TTM) | 3.65 |
| Earnings date | 07 Feb 2024 - 12 Feb 2024 |
| Forward dividend & yield | 6.20 (4.30%) |
| Ex-dividend date | 12 Jan 2024 |
| 1y target est | 169.88 |
Insider Monkey12 Best Healthcare Dividend Stocks To Buy Now
In this article, we discuss 12 best healthcare dividend stocks to buy now. You can skip our detailed analysis of the healthcare sector and the past performance of dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks To Buy Now. Over the span of almost four years, the COVID-19 pandemic brought about […]
ZacksAbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
- PR Newswire
AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences, today announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with AbbVie, BigHat will utilize its Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high quality antibodies for multiple therapeutic targets.
